The correction concerns the date in the English version of the press release entitled "Idogen has successfully completed the optimization of the GMP manufacturing process for the first clinical study with its tolerogenic cell therapy IDO 8". The press release must rightly be dated 06 December 2021, which appears from the Swedish version which was published at the same time.

 

The online english version of the press release has been adjusted.

 

For further information, please contact:

Anders Karlsson, CEO, Idogen AB

Phone: +46 70 918 00 10

Email: anders.karlsson@idogen.com

 

Certified Adviser:
Erik Penser Bank AB, Box 7405, 103 91 Stockholm
Phone: +46 (0)8-463 80 00
Email: certifiedadviser@penser.se

 

The information was submitted for publication through the above contact person on 06 December 2021, 09:18 CET

 

Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com

https://news.cision.com/idogen/r/correction-of-date-in-press-release---idogen-has-successfully-completed-the-optimization-of-the-gmp-,c3466422

https://mb.cision.com/Main/12368/3466422/1505925.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English